Floatz logo

Aliskiren

Proteinuric Kidney Disease

Columbia UniversitySmall moleculePhase 4 / ApprovedDormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Proteinuric Kidney Disease cohort.

Asset / SponsorPhaseRating
VALSARTAN
Columbia University
Phase 4BB
Semaglutide
University Medical Center Groningen
Phase 3BB
Huaier Granule
Fudan University
Phase 2CCC
Losartan
University of Alabama at Birmingham
Phase 2CCC
Empagliflozin
University of Illinois at Chicago
Phase 2CCC
Enalapril
University of Alabama at Birmingham
D
Paricalcitol
Federico II University
N/AD

Same molecule, other indications

Aliskiren is also rated in:

hypertensive disorderDormant
BB
Indicative ·
68 / 100
View asset →
Abdominal ObesityDormant
B
Indicative ·
60 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →